Clinical Experience with URO17(®) in the Diagnosis and Surveillance of Bladder Cancer
Publication Title
J Clin Med
Document Type
Article
Publication Date
11-16-2025
Keywords
URO17®; bladder cancer; cystoscopy; hematuria; keratin 17 (K17); non-muscle-invasive bladder cancer (NMIBC); noninvasive diagnostics; urinary biomarker; urine cytology; urothelial carcinoma.; california; santa monica; psjhc
Abstract
Objective: To describe the clinical use of URO17®, a noninvasive, urine-based immunocytochemistry assay targeting Keratin 17 (K17), as an adjunct to conventional diagnostic methods for urothelial carcinoma. Materials and Methods: These illustrative cases summarize the real-world use of URO17® in diagnostic workflows for patients presenting with hematuria and those undergoing surveillance for non-muscle invasive bladder cancer (NMIBC). Urine samples were processed via standard immunocytochemistry and interpreted alongside cystoscopic, cytological, and radiographic findings. Discussion: URO17® was used as a complementary diagnostic tool to help guide clinical management. Negative results supported deferral of invasive procedures in selected patients, while positive findings prompted further evaluation when standard tests were inconclusive. Conclusions: In the seven illustrative cases presented, URO17® aided clinical decision-making as part of routine diagnostic and surveillance workflows. The test's integration with existing cytology processes supports its potential role as a noninvasive adjunct for evaluating patients with suspected or recurrent urothelial carcinoma.
Area of Special Interest
Cancer
Specialty/Research Institute
Oncology
Specialty/Research Institute
Urology
DOI
10.3390/jcm14228108
